Cancer Caregiver Burden: Targeting Emotion Regulation in a Trial (ERT-ICs)

March 19, 2025 updated by: University of Aarhus

Cancer Caregiver Burden: Targeting Emotion Regulation in a Randomized Controlled Trial

Informal caregivers of cancer patients report high levels of psychological distress as evidenced in markedly increased levels of anxiety and depression. High levels of psychological distress in caregivers have also been found to be associated with poorer health and increased levels of pro-inflammatory cytokines that are well-established risk factors for physical illness and stress-related mortality. Previous psychological interventions using cognitive methods have only produced small effect sizes and more research on how to effectively alleviate caregiver burden is needed. The proposed project will investigate the effect of Emotion Regulation Therapy (ERT) for caregivers of cancer patients. ERT is a novel approach specifically targeting emotion regulation with the aim of improving mental and physical health. The effect of ERT will be examined in a randomized controlled trial comparing ERT to usual medical care (UMC).

Study Overview

Status

Completed

Conditions

Detailed Description

PURPOSE:

The primary purpose of the study is to test the efficacy of Emotion Regulation Therapy (ERT) for informal caregivers (ICs) of cancer patients. ERT is a manualized treatment for ICs and consists of 8 weekly sessions.

AIMS AND HYPOTHESES:

Intervention and mediation effects. In an RCT, the investigators will investigate the efficacy of an 8 session ERT for ICs on psychological and physical distress and a number of other health outcomes in both ICs and cancer patients. Outcomes in the ERT group will be compared to outcomes in a group of ICs and patients receiving usual medical care (UMC) (see Figure 1). ICs receiving ERT compared to ICs receiving UMC are expected to exhibit 1a) significant reductions in psychological distress and perceived caregiving burden, 1b) improvements in quality of life; and 1c) improvements in pro-inflammatory markers of stress/immune functioning. Likewise, patients whose ICs receive ERT are expected to report 2a) reduced anxiety and depression, 2b) improved quality of life and 2c) less chronic inflammation. Due to the design, these effects will be considered following the acute treatment period (pre, mid and post therapy). In addition to this, gains are expected to be maintained over the follow-up-period. In addition, 3) improvements are exptected to be maintained over the follow-up period. Finally, 4) improvements in adaptive emotion regulation (mindfulness, acceptance, and cognitive reappraisal) are expected to mediate the effect of ERT.

PARTICIPANTS AND PROCEDURES:

ICs of cancer patients with various cancer types will be consecutively recruited from Aarhus University Hospital, Denmark. Staff at the Outpatient Clinic at the Department of Oncology, Aarhus University Hospital, Denmark, will screen ICs at the department. Initially the investigators wanted to include caregivers of patients with lung and colorectal cancer only. However, in order to be able to include caregivers at a faster pace, it was decided - after one month during which only two caregivers were included - to broaden the patient group. Furthermore, it was decided that more than one IC per patient could participate.

After giving informed consent, participants will be randomized to Emotion Regulation Therapy (ERT) or usual medical care (UMC) in a ratio of 1:1 by means of computer-generated randomization lists. Outcome measures will be obtained pre-, mid-, and post-therapy as well as at 3 and 6-month follow-up. At every ERT session, ICs and clinicians will fill out a number of self-report the process measures. Cancer patients will be assessed pre- and post ERT, and at 3 and 6-months follow-up. Every IC and patient will provide blood samples before and after the intervention as well as at follow-ups.

Based on a power calculation (alpha=0.0125, beta=0.90), a dropout rate of 35%, and an intraclass correlation between ICs of the same patient of 0.20, the inclusion of 80 ICs will allow for an interaction effect between group (ERT vs. UMC) and time (acute treatment, thats is, pre, mid and post) of a medium effect size (d=0.5) to be significant.

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Aarhus C, Denmark, DK8000
        • Unit for Psychooncology and Health Psychology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 69 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Medium levels of distress (distress thermometer > 3) and at least moderate levels of worry or rumination
  • Caregiver of patient with cancer

Exclusion Criteria:

  • an expected survival of the patient of <6 months,
  • active substance abuse (alcohol or drugs), and
  • participation in other psychosocial trials.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Emotion Regulation Therapy
8 sessions of Emotion Regulation Therapy.
8 sessions of ERT
No Intervention: Usual Medical Care
No planned psychotherapy.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in The Caregiver Reaction Assessment and EORTC-QLQ-30
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring burden in ICs and quality of life cancer patients, respectively
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring anxiety and depression
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Penn State Worry Questionnaire
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring worry
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Rumination Response Scale - Brooding subscale only
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring brooding
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Difficulty in Emotion Regulation Scale
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring emotion regulation
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Emotion Regulation Questionnaire
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring emotion regulation
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Five Facet Mindfulness Questionnaire
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring mindfulness
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Experiences Questionnaire
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring psychological distancing
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in The Pittsburgh Sleep Quality Index
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring sleep quality
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in quality of life - WHO-5
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring quality of life
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Change in Pro-inflammatory markers: CRP, TNFalpha, IL-1, IL-6
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, and post-therapy).
Serum-derived pro-inflammatory markers (only pre and post therapy)
Between-group effect at post, based on the whole treatment duration (pre-, and post-therapy).
Emotional closeness
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
2 items (actual and wanted emotional closeness) rated on a 0-10 scale
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Emotional attention coping (EAC)
Time Frame: Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).
Questionnaire measuring emotion regulation
Between-group effect at post, based on the whole treatment duration (pre-, mid- and post-therapy).

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mia S O'Toole, MSc, University of Aarhus

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2015

Primary Completion (Actual)

June 25, 2018

Study Completion (Actual)

December 31, 2018

Study Registration Dates

First Submitted

December 4, 2014

First Submitted That Met QC Criteria

December 22, 2014

First Posted (Estimated)

December 23, 2014

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 19, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety Depression

Clinical Trials on Emotion Regulation Therapy

Subscribe